BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $214,965,332 | -16.7% | 3,158,004 | -0.1% | 3.30% | -10.0% |
Q2 2023 | $258,023,614 | +6.6% | 3,160,892 | -3.1% | 3.66% | +1.2% |
Q1 2023 | $242,035,750 | -11.5% | 3,262,377 | -1.2% | 3.62% | -20.1% |
Q4 2022 | $273,627,657 | +17.0% | 3,301,492 | +301.0% | 4.53% | +38.1% |
Q3 2022 | $233,818,000 | -19.7% | 823,303 | -1.9% | 3.28% | -15.9% |
Q2 2022 | $291,034,000 | -26.8% | 839,587 | -8.6% | 3.90% | -1.5% |
Q1 2022 | $397,673,000 | -22.1% | 918,328 | -6.9% | 3.96% | -6.3% |
Q4 2021 | $510,513,000 | +5.2% | 986,803 | -1.5% | 4.22% | +6.3% |
Q3 2021 | $485,350,000 | -0.5% | 1,001,610 | -7.6% | 3.98% | +7.5% |
Q2 2021 | $488,024,000 | -4.7% | 1,083,872 | -19.2% | 3.70% | -3.0% |
Q1 2021 | $512,224,000 | +7.7% | 1,341,147 | -10.5% | 3.81% | +16.0% |
Q4 2020 | $475,764,000 | +25.6% | 1,498,233 | -2.0% | 3.29% | +4.7% |
Q3 2020 | $378,743,000 | -6.3% | 1,528,854 | -0.2% | 3.14% | -9.7% |
Q2 2020 | $404,357,000 | +37.0% | 1,531,250 | -1.6% | 3.48% | +1.6% |
Q1 2020 | $295,140,000 | -18.1% | 1,556,483 | -5.2% | 3.42% | -0.7% |
Q4 2019 | $360,303,000 | +12.4% | 1,641,397 | +0.2% | 3.45% | +10.8% |
Q3 2019 | $320,614,000 | -6.2% | 1,638,547 | -0.0% | 3.11% | -4.0% |
Q2 2019 | $341,704,000 | +3.0% | 1,638,947 | -1.9% | 3.24% | -3.4% |
Q1 2019 | $331,717,000 | +34.6% | 1,670,699 | -1.9% | 3.35% | +13.1% |
Q4 2018 | $246,375,000 | -41.6% | 1,702,424 | -17.7% | 2.96% | -22.7% |
Q3 2018 | $422,122,000 | +44.0% | 2,068,108 | +4.4% | 3.83% | +27.5% |
Q2 2018 | $293,057,000 | -2.5% | 1,980,782 | -0.4% | 3.01% | -11.9% |
Q1 2018 | $300,503,000 | +14.5% | 1,989,561 | -1.8% | 3.41% | +7.1% |
Q4 2017 | $262,429,000 | +2.4% | 2,025,700 | -4.4% | 3.19% | +2.2% |
Q3 2017 | $256,179,000 | +1.5% | 2,119,107 | -1.3% | 3.12% | +0.8% |
Q2 2017 | $252,311,000 | +15.6% | 2,147,328 | -0.0% | 3.09% | +6.2% |
Q1 2017 | $218,313,000 | -7.3% | 2,147,690 | -6.3% | 2.91% | -15.4% |
Q4 2016 | $235,585,000 | -4.8% | 2,291,016 | +1.4% | 3.44% | -5.4% |
Q3 2016 | $247,476,000 | -2.9% | 2,260,053 | +0.0% | 3.64% | -9.6% |
Q2 2016 | $254,805,000 | +8.3% | 2,259,507 | -9.2% | 4.03% | +3.4% |
Q1 2016 | $235,192,000 | +6.6% | 2,488,278 | +1.5% | 3.89% | +12.6% |
Q4 2015 | $220,710,000 | -2.1% | 2,452,328 | +0.6% | 3.46% | -10.5% |
Q3 2015 | $225,432,000 | -1.2% | 2,438,158 | +5.2% | 3.86% | +2.8% |
Q2 2015 | $228,181,000 | -1.8% | 2,317,266 | -0.0% | 3.76% | -2.0% |
Q1 2015 | $232,401,000 | +7.9% | 2,317,290 | -0.6% | 3.83% | +3.1% |
Q4 2014 | $215,480,000 | – | 2,332,040 | – | 3.72% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |